An interventional study of Wearable Eye-Tracking Assessment During Structured Bimanual Tasks in Cerebral Palsy (CP), sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by Samsung Medical Center · Not applicable, Interventional, and Other
Among 56 studies in Cerebral Palsy with a site in Korea, Republic of — 7 open to participants now, 8 under way, none of them phase 3. Cerebral Palsy · Korea, Republic of.
Among the 56 studies in Cerebral Palsy with a site in Korea, Republic of, this one is the 17th largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2026, is one of 31 with no phase, and was the 54th registered.
1,936 studies on the registry are indexed under Cerebral Palsy; 458 are open to participants now.
Browse Cerebral Palsy studies →7 of the 56 studies in Cerebral Palsy with a site in Korea, Republic of are open now. Recruiting first, the newest first:
COSMO ROBOTICS CO., Ltd · Sites in Korea, Republic of
Yonsei University · Sites in Korea, Republic of
Zeng Changhao · Sites in Korea, Republic of
Ju Seok Ryu · Sites in Korea, Republic of
Yonsei University · Sites in Korea, Republic of
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 270 Cerebral Palsy studies recruiting now, 27 (10%) set no upper age limit and 235 (87%) stop at 75 or younger; 255 take children under 18; 51 take healthy volunteers.
This study: 6 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 7
First in 2010; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 40 is above the median of 34 across 1,431 interventional studies indexed under Cerebral Palsy.
Median enrollment 31 across the 46 interventional studies, 69 across the 10 observational. Of the 42 that completed or were terminated, 9 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 56 have an industry lead sponsor. The 10 most frequent:
Samsung Medical Center is the lead sponsor of 1,011 studies on the registry; 152 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Samsung Medical Center has 5 studies filed under Cerebral Palsy — fewer than ten, so there is no comparison to draw.
3 of the studies in Cerebral Palsy with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07539389COSMO ROBOTICS CO., LtdSafety and Effectiveness of Bambini Kids Robot-Assisted Gait Training (RAGT) in Children With Cerebral Palsy | 2026-12-31 |
| NCT07806994Samsung Medical CenterWearable Eye Tracking During Bimanual Tasks in Children With Cerebral Palsy | 2027-07-30 |
| NCT07777809Sahmyook UniversityBilateral Asymmetry of Respiratory Muscle Activity During Breathing in Children With Spastic Cerebral Palsy | 2027-08 |
Among the 56 studies in Cerebral Palsy with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational pilot study will include 40 children and adolescents aged 6 to 12 years: 20 with cerebral palsy and 20 with typical development. The main purpose is to determine whether Pupil Labs Neon wearable eye-tracking glasses can be used reliably while participants perform structured tasks using both hands.
Each participant will attend one study visit. After assessments of near vision, hand function, visual perception, visual-motor function, and attention-related characteristics, participants will wear the eye-tracking glasses. They will view an instruction card, find target objects, and place the objects into boxes using both hands. The tasks will be completed under three conditions that vary visual-search and sequencing demands, with breaks provided as needed.
Researchers will evaluate whether the planned procedures can be completed and whether the recordings provide usable eye-tracking data. Exploratory analyses will examine how gaze and hand actions are coordinated and whether these patterns differ between the cerebral palsy and typical-development groups or across task conditions. No treatment will be provided, and the study is not designed to evaluate treatment effectiveness. The findings will be used to improve the measurement protocol and quality-control procedures for future research.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General Inclusion Criteria
Children aged 6-12 years
Cerebral Palsy Group
Typically Developing Group
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children with unilateral cerebral palsy complete one study visit involving wearable eye tracking during structured visual-search and goal-directed bimanual tasks under a standard condition, an increased visual-search-demand condition, and an increased sequencing-demand condition. The order of task conditions is counterbalanced. The same assessment protocol is administered to the typically developing comparison arm. The procedure is conducted for research measurement only and does not provide treatment or alter clinical care.
Other: Wearable Eye-Tracking Assessment During Structured Bimanual Tasks
Typically developing children complete the same single-visit wearable eye-tracking and structured task-assessment protocol as the cerebral palsy arm. Participants perform structured visual-search and goal-directed bimanual tasks under a standard condition, an increased visual-search-demand condition, and an increased sequencing-demand condition. The order of task conditions is counterbalanced. This arm serves as the pre-specified comparison arm. The procedure does not provide treatment or alter clinical care.
Other: Wearable Eye-Tracking Assessment During Structured Bimanual Tasks
Participants wear the Pupil Neon eye-tracking system during one study visit while performing structured visual-search and goal-directed bimanual tasks under a standard condition, an increased visual-search-demand condition, and an increased sequencing-demand condition. The order of conditions is counterbalanced. The system records two-dimensional gaze coordinates and egocentric scene video to evaluate protocol feasibility, data quality, and exploratory gaze-behavior measures. The assessment is research-specific and does not provide treatment, rehabilitation training, visual cues, stimulation, or performance feedback and does not alter clinical care.
Successful Gaze-Position Verification Rate
Percentage of participants for whom gaze position is successfully verified at predefined central and task-relevant locations before task recording, after offset correction when needed. The rate will be calculated as the number with successful verification divided by the number attempting eye-tracker setup, multiplied by 100. Reasons for unsuccessful verification will be recorded.
Time frame: Day 1, before structured task recording
Wearable Eye-Tracking Protocol Completion Rates
Three completion percentages will be calculated separately: (1) participants successfully fitted with the Pupil Neon and starting recording divided by all enrolled participants; (2) participants completing all three planned task conditions divided by those starting the wearable eye-tracking assessment; and (3) participants completing each condition divided by those scheduled for that condition. Each value will be multiplied by 100. Reasons for noncompletion will be categorized.
Time frame: Day 1, during the single study visit (up to 180 minutes)
Mean Valid Gaze Data Proportion
Percentage of sampled time points within each predefined analysis interval for which a valid two-dimensional gaze coordinate is available. Values range from 0 to 100, with higher values indicating more complete gaze data. Results will be summarized by task condition and study group. Trials with less than 70 percent valid gaze data will be flagged for quality control but retained in the feasibility denominator.
Time frame: Day 1, during the structured eye-tracking task assessment (up to 180 minutes)
Analyzable Eye-Tracking Trial Rate
Percentage of attempted trials with synchronized scene video, gaze coordinates, and task-event annotations sufficient to derive the predefined area-of-interest and event measures. The rate will be calculated as the number of analyzable trials divided by all attempted trials, multiplied by 100. Reasons for non-analyzability will be categorized as device slippage, field-of-view occlusion, lighting problems, signal loss, missing data streams, synchronization failure, or other.
Time frame: Day 1, during the structured eye-tracking task assessment (up to 180 minutes)
Mean Total Study Assessment Duration
Elapsed time in minutes from initiation of the first study assessment after consent to completion or discontinuation of the final planned assessment, including rest breaks. Duration will be summarized separately for each study group.
Time frame: Day 1, from initiation of the first study assessment through completion or discontinuation of the final planned assessment (up to 180 minutes)
Number of Participants With Assessment-Related Discomfort or Protocol Interruption
Number and percentage of participants experiencing fatigue, eye strain, pressure from the eye-tracking glasses, headache, dizziness, upper-limb fatigue, distress or refusal, or other discomfort, and participants requiring a pause, device adjustment, or early discontinuation. Events will be summarized by type, severity, action taken, and resolution.
Time frame: Day 1, from the start of the study visit through the immediate post-assessment period (up to 180 minutes)
Mean Overall and Phase-Specific Task Performance Time
Mean time in seconds from task onset to task completion and for the predefined phases of instruction-card viewing, visual search, object selection, transport, insertion, and phase transition. Each timing measure will be reported separately by task condition and study group.
Time frame: Day 1, during the structured eye-tracking task assessment (up to 180 minutes)
Mean Number of Task Errors and Instruction-Card Rechecks per Trial
Mean number per trial of incorrect object selections, sequence errors, and returns to the instruction card. Each event type will be reported separately by task condition and study group. Higher counts indicate more frequent task-performance disruptions.
Time frame: Day 1, during the structured eye-tracking task assessment (up to 180 minutes)
Mean Time to First Target Fixation
Mean time in seconds from the trial-start event to the onset of the first valid fixation within the target area of interest. Longer times indicate slower visual identification of the target.
Time frame: Day 1, during the structured eye-tracking task assessment (up to 180 minutes)
Mean Area-of-Interest-Specific Fixation-Time Proportion
Percentage of total valid fixation duration within the analysis interval allocated to each predefined area of interest, including the target, non-target items, and distractors. Each area-of-interest proportion will be reported separately by task condition and study group.
Time frame: Day 1, during the structured eye-tracking task assessment (up to 180 minutes)
Plan to share: No — Individual participant data will not be shared because the study involves minors and includes potentially identifiable eye-tracking recordings and linked clinical assessment data.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.
Of 902 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 10 months is below that.
Counting every sponsor, half of 921 studies reached it within 12 months; a quarter within 5 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.